PERTAIN研究:一线曲妥珠单抗联合芳香化酶抑制剂±帕妥珠单抗治疗HER2阳性HR阳性转移性/局部晚期乳腺癌的随机开放II期试验
PERTAIN是一项随机开放多中心II期试验,纳入HER2阳性、激素受体阳性转移性/局部晚期乳腺癌患者,随机接受帕妥珠单抗+曲妥珠单抗+芳香化酶抑制剂或曲妥珠单抗+芳香化酶抑制剂。结论认为帕妥珠单抗联合曲妥珠单抗和芳香化酶抑制剂有效,安全性与此前研究一致。
要点
- 帕妥珠单抗+曲妥珠单抗+AI一线治疗HER2阳性HR阳性MBC/LABC较曲妥珠单抗+AI显著延长PFS。
- 安全性与此前帕妥珠单抗联合曲妥珠单抗研究一致,无治疗相关死亡。
核心结论
- PERTAIN研究达到主要终点PFS,帕妥珠单抗联合曲妥珠单抗和芳香化酶抑制剂对HER2阳性MBC/LABC有效。
研究设计与样本
- PERTAIN(NCT01491737)为正在进行的随机、开放、多中心(80个中心、8个国家)II期试验。
- 患者为HER2阳性、激素受体阳性MBC/LABC,除内分泌治疗外未接受过既往全身治疗。
- 1:1随机接受静脉帕妥珠单抗(840mg负荷后420mg每3周)+曲妥珠单抗(8mg/kg后6mg/kg每3周)+口服阿那曲唑(1mg每日)或来曲唑(2.5mg每日),或曲妥珠单抗+AI。
- 诱导化疗(多西他赛每3周或紫杉醇每周,18-24周)由研究者决定(随机前决定但随机后给予)。
- 主要终点为PFS,按是否接受诱导化疗和辅助内分泌治疗结束时间分层。
主要发现
- 分层中位PFS在帕妥珠单抗+曲妥珠单抗组为18.89个月(95%CI 14.09-27.66),曲妥珠单抗组为15.80个月(95%CI 11.04-18.56)。
- 安全性人群中,帕妥珠单抗+曲妥珠单抗组严重不良事件报告42/127(33.1%),曲妥珠单抗组24/124(19.4%)。
- ≥3级不良事件率分别为64/127(50.4%)和48/124(38.7%);无因不良事件导致的死亡。
关键数值与推荐
- 帕妥珠单抗剂量:840mg负荷后420mg每3周静脉给药。
- 曲妥珠单抗剂量:8mg/kg负荷后6mg/kg每3周静脉给药。
- 阿那曲唑1mg每日口服或来曲唑2.5mg每日口服。
- 诱导化疗可选多西他赛每3周或紫杉醇每周,持续18-24周。
临床怎么用
- 对于HER2阳性、激素受体阳性转移性/局部晚期乳腺癌患者,一线可考虑帕妥珠单抗联合曲妥珠单抗和芳香化酶抑制剂。
- 是否联合诱导化疗可由研究者根据患者情况决定。
- 治疗期间需关注不良事件,尤其是严重不良事件和≥3级不良事件的发生。
局限性
- 诱导化疗由研究者决定,可能引入选择偏倚。
- 开放标签设计可能影响部分终点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC). PATIENTS AND METHODS: The PERTAIN trial (NCT01491737) is an ongoing randomized, open-label, multicenter-80 sites and eight countries-phase II trial. Patients have HER2-positive, hormone receptor-positive MBC/LABC and no prior systemic therapy with the exception of endocrine. Random assignment was 1:1 to intravenous pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) plus trastuzumab (8 mg/kg followed by 6 mg/kg every 3 weeks), and oral anastrozole (1 mg every day) or letrozole (2.5 mg every day), or trastuzumab and an AI. Induction intravenous docetaxel every 3 weeks or paclitaxel every week could be administered for 18 to 24 weeks at the investigator's discretion (decided before but given after random assignment). Primary end point was progression-free survival (PFS). Patients were stratified by whether they received induction chemotherapy and their time since adjuvant hormone therapy. RESULTS: One hundred twenty-nine patients were randomly assigned per arm (February 2012 to October 2014; intent-to-treat populations); 75 in one arm and 71 in the other were chosen to receive induction chemotherapy. Stratified median PFS was 18.89 months (95% CI, 14.09 to 27.66 months) in the pertuzumab plus trastuzumab arm and 15.80 months (95% CI, 11.04 to 18.56 months) in the trastuzumab arm (stratified hazard ratio, 0.65; 95% CI, 0.48 to 0.89; P = .0070). Serious adverse events (AEs) were reported for 42 (33.1%) of 127 and 24 (19.4%) of 124 patients in the safety populations of the pertuzumab plus trastuzumab and trastuzumab arms, respectively. Rates of grade ≥ 3 AEs were 64 (50.4%) of 127 and 48 (38.7%) of 124, respectively. There were no deaths as a result of AEs. CONCLUSION: PERTAIN met its primary PFS end point. Pertuzumab plus trastuzumab and an AI is effective for the treatment of HER2-positive MBC/LABC. The safety profile was consistent with previous trials of pertuzumab plus trastuzumab.
引用
- Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol. 2018. PMID: 30106636. doi:10.1200/JCO.2017.76.7863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。